Newark, DE – Distinguished Delaware physicians, scientists and entrepreneurs will meet with colleagues from around the world tomorrow at the University of Delaware’s STAR campus to discuss exciting work being done in the fields of translational medicine and oncology research here in the State.
Members of the international bio-science community will meet with Governor Jack Markell in the morning, followed by a lively discussion with area experts to learn about ground-breaking work being done here in the search for tests, tools and treatment that can be used to combat diseases such as cancer. They will also take a tour of the state-of-the-art facilities at UD’s STAR campus and hear details about the wet lab incubators currently under construction at UD and at Delaware State University.
This exclusive one-day event comes at the conclusion of the week-long International BIO Convention in Philadelphia and demonstrates Delaware’s prowess for moving R&D innovations to the marketplace.
“Delaware is committed to providing companies with the support and resources needed to convert research into results that can be used to detect disease, equip caregivers and provide patients with treatment and therapies,” said Governor Jack Markell. “Our small state makes it easier for researchers to connect with community healthcare facilities and accomplished healthcare providers to accelerate the pace of moving medicines, equipment and therapies from the lab bench to the patient’s bedside.”
The event features some of the brightest minds in the State, including scientists from the Center for Translational Cancer Research and DSU’s Optical Science Center for Applied Research, as well as executives from bio-science start-ups Genome Profiling and Incyte and from Delaware Technology Park. Industry veteran Ian Wright and Dean of UD’s College of Health Sciences Kathleen Matt are hosting the event.
“This is a unique opportunity for international bio-science executives and scientists to connect with an exceptional group of professionals doing cutting-edge research, and to appreciate how Delaware provides the perfect environment for this caliber of work,” said Ian Wright. “We are confident that we will provide our colleagues from [list countries] with serious food for thought as they contemplate the best place in the U.S. to bring their bio-science business.”
Bio-science heavyweights share their work
Speakers at the event will include:
Noureddine Melikechi, founding Director of DSU’s Optical Science Center for Applied Research (OSCAR) and a member of the Mars Science Laboratory team, whose research interests include the development of sensitive optical techniques for the early detection of cancers in biomedical fluids.
Herve Hoppenot, CEO, President, Chairman of the Board of Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small-molecule drugs, primarily for oncology.
Jeb Connor and Adam Marsh, co-founders of Genome Profiling (GenPro), a bioinformatics company specializing in the discovery of novel epigenetic biomarkers based on our proprietary, genome-wide methylation profiling platform to revolutionize the way we treat, diagnose, and predict chronic and life-threatening diseases.
Prominent scientists from the Center for Translational Cancer Research, a collaboration of the Helen F. Graham Cancer Center & Research Institute, the University of Delaware, A.I. duPont Children’s Hospital and the Delaware Biotechnology Institute, will also participate:
Bruce M. Boman, attending Physician and Director for Cancer Genetics and Stem Cell Biology at the Center and a leading expert on colorectal cancer and genetics.
Nicholas Petrelli, Endowed Medical Director who led efforts to rebuild the cancer program, in collaboration with the Delaware Cancer Consortium, resulting in the Delaware cancer mortality rate falling twice as fast as the national rate.
Jennifer-Sims Mourtada, Senior Clinical Scientist at the Center for Translational Cancer Research whose current work focusses on identifying markers to predict how aggressively breast cancer may progress in individual patients to help doctors diagnose using less invasive methods.
Eric Kmiec, Director, Gene Editing Institute. Widely recognized for his pioneering work in the fields of molecular medicine and gene editing, and co-founder of ETAGEN, a new start-up centered on gene editing. Faculty member Delaware State University.
In addition, Delaware Technology Park Chairman and CEO Mike Bowman will address how public/private partnerships are supporting the launch and growth of bio-science companies in the State.
The Delaware’s State-of-the-Art Facilities
The event will also showcase the brand new wet lab incubators currently under construction at the University of Delaware and Delaware State University. DSU’s gleaming OSCAR laboratory will soon open its doors to business innovators, offering space and equipment for high-end optical research and testing. At the Delaware Technology Park on UD’s STAR Campus, a new wet laboratory incubator will provide health science companies with turnkey facilities to launch operations quickly and efficiently.
“Delaware has the whole package: Cutting-edge facilities, an engaged team of public officials, a dynamic community of scientific experts, and the quality of life that companies seek when looking to start up new operations,” says Delaware Technology Park’s Mike Bowman. “We look forward to sharing the details with our guests and demonstrating how Delaware can deliver.”